Araya-Sibaja Andrea Mariela, Vega-Baudrit José Roberto, Guillén-Girón Teodolito, Navarro-Hoyos Mirtha, Cuffini Silvia Lucia
Laboratorio Nacional de Nanotecnología LANOTEC-CeNAT-CONARE, Pavas 1174-1200, San José, Costa Rica.
Centro de Investigación y Extensión en Materiales, Escuela de Ciencia e Ingeniería de los Materiales, Tecnológico de Costa Rica, Cartago 159-7050, Costa Rica.
Pharmaceutics. 2019 Mar 9;11(3):112. doi: 10.3390/pharmaceutics11030112.
Lovastatin (LOV) is a drug used to treat hypercholesterolemia. Recent studies have identified its antioxidant effects and potential use in the treatment of some types of cancer. However, the low bioavailability related to its poor water solubility limits its use in solid oral dosage forms. Therefore, to improve the solubility of LOV three eutectic systems of LOV with the carboxylic acids benzoic (BEN), salicylic (SAL) and cinnamic (CIN) were obtained. Both binary phase and Tammann diagrams were constructed using differential scanning calorimetry (DSC) data of mixtures prepared from 0.1 to 1.0 molar ratios. Binary mixtures and eutectics were prepared by liquid-assisted grinding. The eutectics were further characterized by DSC and powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). The LOV-BEN, LOV-SAL and LOV-CIN system formed a eutectic at an LOV mole fraction of 0.19, 0.60 and 0.14, respectively. The systems exhibited improvements in LOV solubility, becoming more soluble by five-fold in the LOV-SAL system and approximately four-fold in the other two systems. Considering that the solubility enhancements and the carboxylic acids used are generally recognized as safe by the U.S. Food and Drug Administration (FDA), the LOV eutectic systems are promising materials to be used in a solubility enhancement strategy for pharmaceutical product formulation.
洛伐他汀(LOV)是一种用于治疗高胆固醇血症的药物。最近的研究已经确定了其抗氧化作用以及在某些类型癌症治疗中的潜在用途。然而,由于其水溶性差导致生物利用度低,限制了它在固体口服剂型中的应用。因此,为了提高洛伐他汀的溶解度,制备了洛伐他汀与苯甲酸(BEN)、水杨酸(SAL)和肉桂酸(CIN)这三种羧酸的共晶体系。使用由0.1至1.0摩尔比制备的混合物的差示扫描量热法(DSC)数据构建二元相图和塔曼图。通过液体辅助研磨制备二元混合物和共晶。通过DSC、粉末X射线衍射(PXRD)、傅里叶变换红外光谱(FT-IR)和扫描电子显微镜(SEM)对共晶进行进一步表征。LOV-BEN、LOV-SAL和LOV-CIN体系分别在LOV摩尔分数为0.19、0.60和0.14时形成共晶。这些体系在洛伐他汀的溶解度方面有改善,在LOV-SAL体系中溶解度提高了五倍,在其他两个体系中提高了约四倍。鉴于溶解度的提高以及所使用的羧酸通常被美国食品药品监督管理局(FDA)认为是安全的,洛伐他汀共晶体系是用于药物产品配方溶解度增强策略的有前景的材料。